On the same day North Carolina hospitals reported a record number of COVID-19 patients in intensive care units across the state, Gov. Roy Cooper signaled he will take action expanding access to a ...

As new COVID variants rise in the U.S., antibodies are getting wiped off the list of treatments. NPR's Pien Huang explains why these infusion treatments didn't last and how scientists are searching ...

The U.S. Food and Drug Administration has pulled its emergency authorization for the only remaining antibody treatment currently being used for non-hospitalized individuals with mild-to-moderate COVID ...

UnitedHealth Group is partnering with Eli Lilly to test the efficacy of its COVID-19 monoclonal antibody treatment, bamlanivimab, for patients at high risk of adverse outcomes. Bamlanivimab has not ...

The exact mechanism responsible for infusion-related reactions (IRRs) after monoclonal antibody (mAb) therapy is unclear. It is also unknown before treatment which patient will develop IRRs. The ...

In the first big real-world test for monoclonal antibodies against malaria a new study has reported extraordinarily promising results, with a novel therapy found to be 88.2% effective at preventing ...

The race is on for new treatments that stand up to omicron's explosive spread. With omicron's explosive spread threatening to outpace current COVID-19 treatments, the race is on to find new options ...

We included 692 patients, of whom 6.7% (n = 47) had experienced one or more IRRs (n = 63). The highest incidence of IRRs (n = 50) were found in patients treated with rituximab (incidence IRR 26%), ...